雷珠单抗联合不同剂量维替泊芬光动力疗法治疗CSC合并CNV的临床疗效  

Clinical Efficacy of Combination Therapy of Ranibizumab and Different Doses of Vitipofen Photodynamic Therapy in the Treatment of CSC Complicated with CNV

作　　者：赖忠燕 曹文捷 周群 宋霞云 高凤娟 吴晓方 LAI Zhongyan;CAO Wenjie;ZHOU Qun(Department of Ophthalmology,Jiading District Central Hospital Affiliated to Shanghai Medical College,Shanghai 201800)

机构地区：[1]上海健康医学院附属嘉定区中心医院眼科,上海201800 [2]复旦大学附属眼耳鼻喉科医院眼科,上海200031

出　　处：《医学临床研究》2024年第2期174-177,共4页Journal of Clinical Research

基　　金：上海市嘉定区自然科学研究课题(JDKW-2021-0026)。

摘　　要：【目的】探讨雷珠单抗联合不同剂量维替泊芬光动力疗法治疗慢性中心性浆液性脉络膜视网膜病变(CSC)合并脉络膜新生血管(CNV)的临床疗效。【方法】选取2014年2月至2019年12月上海健康医学院附属嘉定区中心医院收治的103例慢性CSC合并CNV患者,根据治疗方法的不同分为常规组[58例58眼,采用雷珠单抗+小剂量(1 mg/m^(2))维替泊芬光动力疗法治疗]和观察组[55例55眼,雷珠单抗+采用半剂量(3 mg/m^(2))维替泊芬光动力疗法治疗]。比较两组患者临床疗效、不良反应发生率及治疗前后视网膜下液隆起最高点高度(HPSF)、最佳矫正视力(BCVA)、视网膜中央静脉血流动力学参数[最大血流速度(V_(max))、最低血流速度(V min)]。【结果】观察组总有效率高于常规组(P<0.05)。治疗前,两组患者HPSF、BVCA比较,差异无统计学意义(P>0.05);治疗后,两组患者HPSF均降低,且观察组低于常规组(P<0.05);治疗后,两组患者BCVA均升高,且观察组高于常规组(P<0.05)。治疗前,两组患者V_(max)、V min比较,差异无统计学意义(P>0.05);治疗后,两组患者V_(max)、V min均降低,且观察组低于常规组(P<0.05)。常规组眼压升高1例,恶心、呕吐2例,不良反应发生率为5.17%;观察组眼压升高2例,恶心、呕吐2例,不良反应发生率为7.27%。两组不良反应发生率比较,差异无统计学意义(P>0.05)。【结论】采用雷珠单抗联合半剂量维替泊芬光动力疗法治疗慢性CSC合并CNV的效果显著,可改善患者视力和视网膜中央静脉血流动力学指标,且安全可靠。【Objective】To explore the clinical efficacy of ranibizumab combined with different doses of vitipofen photodynamic therapy in the treatment of chronic central serous chorioretinopathy(CSC)with choroidal neovascularization(CNV).【Methods】A total of 103 patients with chronic CSC complicated with CNV admitted to Jiading District Central Hospital affiliated with Shanghai Health Medical College from February 2014 to December 2019 were selected.According to different treatment methods,they were divided into a conventional group[58 cases,58 eyes,treated with ranibizumab and low-dose(1 mg/m^(2))Vitipofen photodynamic therapy]and an observation group[55 cases,55 eyes,treated with ranibizumab and half dose(3 mg/m^(2))Vitipofen photodynamic therapy].We compared the clinical efficacy,incidence of adverse reactions,height of subretinal fluid protrusion(HPSF),best corrected visual acuity(BCVA),and hemodynamic parameters of the central retinal vein(V_(max) and V min)between two groups of patients before and after treatment.【Results】The total effective rate of the observation group was higher than that of the control group(P<0.05).Before treatment,there was no statistically significant difference in HPSF and BVCA between the two groups of patients(P>0.05);After treatment,HPSF was decreased in both groups,and the observation group was lower than the conventional group(P<0.05).After treatment,BCVA increased in both groups,and the observation group was higher than the conventional group(P<0.05).Before treatment,there was no statistically significant difference in V_(max) and V min between the two groups of patients(P>0.05);After treatment,V_(max) and V min decreased in both groups of patients,and the observation group was lower than the control group(P<0.05).In the conventional group,there was 1 case of elevated intraocular pressure,2 cases of nausea and vomiting,and the incidence of adverse reactions was 5.17%;In the observation group,there were 2 cases of elevated intraocular pressure,2 cases of nausea and vomiting,and

关 键 词：抗体 单克隆/治疗应用 中心性浆液性脉络膜视网膜病变/治疗 光化学疗法 治疗结果 

分 类 号：R774.1[医药卫生—眼科]